
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists work to reduce blood sugar levels by prompting the pancreas to release more insulin and by limiting glucose output from the liver. They are frequently prescribed as an additional therapy when oral diabetes medications like metformin are not enough to keep blood sugar within target ranges. Some of these GLP-1 treatments have further been linked to a reduced risk of heart attacks, strokes, and other heart related problems in patients with type 2 diabetes and existing cardiovascular disease.
In adults who do not have diabetes, GLP-1 agonists like Wegovy and Saxenda are approved by the FDA specifically for weight management. They work by increasing satiety and reducing hunger, which makes it easier to cut back on calories without constant cravings. Clinical research has found that using GLP-1 medications alongside diet and exercise leads to significant long term weight loss for many people.
GLP-1 receptor agonists manage blood sugar by increasing meal stimulated insulin secretion while at the same time reducing glucagon production. This double effect limits sharp rises in blood glucose and promotes more consistent control. Since their activity is glucose dependent, the chance of blood sugar dropping too low is reduced compared with many traditional therapies.
One of the most important benefits of GLP-1 therapy is its role in achieving and maintaining long term weight loss. These medications slow gastric emptying and communicate with appetite centers in the brain to boost satiety, which helps people feel full sooner and stay full longer, resulting in fewer calories consumed. Studies have consistently shown that GLP-1 based drugs like liraglutide, semaglutide, and tirzepatide can lead to significant and durable weight reduction when used alongside lifestyle changes.



GLP-1/GIP co-agonists work by activating receptors for both GLP-1 and GIP, which boosts insulin secretion and tightens appetite control beyond what GLP-1 alone can achieve. This dual incretin effect offers a stronger tool for lowering blood sugar and managing food intake, positioning these drugs as promising therapies for diabetes and obesity.
GLP-1/glucagon co-agonists target receptors for GLP-1 and glucagon together, supporting more effective weight loss and improved energy metabolism, while helping preserve lean body tissue.

